SAB Biotherapeutics, Inc. SEC filings SABS
SAB Biotherapeutics, Inc. has 433 filings in SEC EDGAR's recent list, going back to Dec 7, 2020. Its latest annual report, Form 10-K, was filed on Mar 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 13, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 25-NSE | Delisting notice | Oct 22, 2026 | — |
| EFFECT | Filing | Jan 7, 2026 | — |
| CORRESP | Letter to the SEC | Jan 5, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 2, 2026 | — |
| EFFECT | Filing | Sep 30, 2025 | — |
| CORRESP | Letter to the SEC | Sep 26, 2025 | — |
| CORRESP | Letter to the SEC | Sep 22, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 15, 2025 | — |
| D | Filing | Aug 5, 2025 | — |
| NT 10-Q | Filing | May 15, 2024 | Mar 31, 2024 |
| EFFECT | Filing | Nov 28, 2023 | — |
| CORRESP | Letter to the SEC | Nov 24, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2023 | — |
| D | Filing | Oct 16, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 27, 2023 | — |
| CORRESP | Letter to the SEC | Sep 26, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 25, 2023 | — |
| EFFECT | Filing | Aug 30, 2023 | — |
| CORRESP | Letter to the SEC | Aug 28, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 28, 2023 | — |
| NT 10-Q | Form nt 10-q | Aug 14, 2023 | Jun 30, 2023 |
| AW | Form aw | Jul 31, 2023 | — |
| RW | Form rw | Jun 21, 2023 | — |
| EFFECT | Filing | May 17, 2023 | — |
| CORRESP | Letter to the SEC | May 15, 2023 | — |
| UPLOAD | Letter from the SEC | May 12, 2023 | — |
| EFFECT | Filing | May 9, 2023 | — |
| CORRESP | Letter to the SEC | May 5, 2023 | — |
| UPLOAD | Letter from the SEC | May 4, 2023 | — |
| NT 10-K | Form nt 10-k | Mar 31, 2023 | Dec 31, 2022 |
| EFFECT | Filing | Feb 10, 2023 | — |
| EFFECT | Filing | Feb 8, 2023 | — |
| CORRESP | Letter to the SEC | Feb 8, 2023 | — |
| UPLOAD | Letter from the SEC | Feb 8, 2023 | — |
| EFFECT | Filing | Apr 26, 2022 | — |
| EFFECT | Filing | Dec 15, 2021 | — |
| CORRESP | Letter to the SEC | Dec 13, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 8, 2021 | — |
| NT 10-Q | Filing | Nov 15, 2021 | Sep 30, 2021 |
| 25-NSE | Delisting notice | Oct 22, 2021 | — |
| 425 | Filing | Oct 13, 2021 | — |
| 425 | Filing | Oct 12, 2021 | — |
| 425 | Filing | Oct 7, 2021 | — |
| 425 | Filing | Oct 4, 2021 | — |
| 425 | Filing | Sep 28, 2021 | — |
| 425 | Filing | Sep 27, 2021 | — |
| EFFECT | Filing | Sep 22, 2021 | — |
| 425 | Filing | Sep 22, 2021 | — |
| CORRESP | Letter to the SEC | Sep 22, 2021 | — |
| CORRESP | Letter to the SEC | Sep 21, 2021 | — |
| CORRESP | Letter to the SEC | Sep 16, 2021 | — |
| 425 | Filing | Sep 8, 2021 | — |
| CORRESP | Letter to the SEC | Sep 8, 2021 | — |
| 425 | Filing | Sep 7, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 2, 2021 | — |
| CORRESP | Letter to the SEC | Aug 17, 2021 | — |
| 425 | Filing | Aug 16, 2021 | — |
| 425 | Filing | Aug 12, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 29, 2021 | — |
| 425 | Filing | Jul 21, 2021 | — |
| 425 | Filing | Jul 16, 2021 | — |
| 425 | Filing | Jul 13, 2021 | — |
| 425 | Filing | Jul 12, 2021 | — |
| 425 | Filing | Jul 9, 2021 | — |
| 425 | Filing | Jul 8, 2021 | — |
| 425 | Filing | Jul 8, 2021 | — |
| 425 | Filing | Jul 8, 2021 | — |
| 425 | Filing | Jul 6, 2021 | — |
| DRSLTR | Filing | Jul 2, 2021 | — |
| 425 | Filing | Jun 22, 2021 | — |
| 425 | Filing | Jun 22, 2021 | — |
| NT 10-Q | Filing | May 17, 2021 | Mar 31, 2021 |
| NT 10-K | Filing | Apr 1, 2021 | Dec 31, 2020 |
| EFFECT | Filing | Jan 11, 2021 | — |
| CERT | Filing | Jan 11, 2021 | — |
| 8-A12B | Filing | Jan 8, 2021 | — |
| CORRESP | Letter to the SEC | Jan 8, 2021 | — |
| CORRESP | Letter to the SEC | Jan 8, 2021 | — |
| CORRESP | Letter to the SEC | Jan 7, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 7, 2021 | — |
| CORRESP | Letter to the SEC | Jan 4, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 30, 2020 | — |
Showing 82 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SABS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miami Beach, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1833214
- Former names
- Big Cypress Acquisition Corp. (until Oct 22, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.